TABLE 3.

Change from baseline to week 12 in secondary outcomes (mITT population)

Mean ± SD	Placebo (n = 233)	Estradiol (n = 239)	Pa
Atrophyb	−0.5 ± 0.8	−0.9 ± 0.8	<0.001
Pallorb	−0.6 ± 0.8	−0.9 ± 0.8	<0.001
Drynessb	−0.5 ± 0.9	−0.9 ± 0.9	<0.001
Friabilityb	−0.6 ± 1.0	−1.0 ± 1.0	<0.001
Petechiaeb	−0.3 ± 0.8	−0.6 ± 0.9	<0.001
pH	−0.53 ± 0.93	−1.35 ± 0.89	<0.001
Percentage of vaginal cells
Superficial	1.2 ± 5.4	10.5 ± 17.2	<0.001
Parabasal	−14.9 ± 39.9	−48.2 ± 45.7	<0.001

Italic values indicate significance.

mITT, modified intent-to-treat.

^aAnalysis of covariance on rank vs placebo.

^bVisual inspection score: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.